Table 1.

Characteristics and methodological quality of included studies.

Study ID	Sample	Diagnosis standard	Intervention	Control	Course (week)	Outcome measure
Liu et al., 2009 [30]	118	Hypertension diagnostic criteria (unclear)	YQG 4 g tid + control	Valsartan 80 mg qd	4	BP; adverse effect
Chen et al., 2006 [31]	130	Hypertension diagnostic criteria (unclear)	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	8	BP; adverse effect
Ji and Han, 2011 [32]	160	1999 WHO-ISH GMH	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	12	BP; adverse effect
Yuan, 2006 [33]	103	1999 WHO-ISH GMH	YQG 4 g tid + control	Valsartan 80 mg qd	2	BP; adverse effect
Shi, 2011 [34]	80	1999 WHO-ISH GMH	YQG 4 g tid + control	Felodipine 5 mg qd	4	BP
Li and Wan, 2006 [35]	80	CGMH-2005; GCRNDTCM; DCBSY	YQG 4 g tid + control	Indapamide 1.25 mg qd	3	BP; adverse effect
Liang, 2011 [36]	100	Hypertension diagnostic criteria (unclear)	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	8	BP; adverse effect
Fu and Xiao, 2011 [37]	992	Hypertension diagnostic criteria (unclear)	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	4	BP
Yang et al., 2008 [38]	122	CGMH-2005; GCRNDTCM	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	4	BP; adverse effect
Lin and Zhou, 2004 [39]	100	Hypertension diagnostic criteria (unclear)	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	2	BP
Ai, 2012 [40]	102	CGMH-2005	YQG 4 g tid + control	Antihypertensive drugs (no detailed information)	6	BP
Qin, 2008 [41]	68	Hypertension diagnostic criteria (unclear)	YQG 4 g tid + control	Enalapril 10 mg qd	4	BP; adverse effect